Study finds Novo's tablet for vaginal atrophy increases compliance compared to creams

A study found that tablets increase compliance among postmenopausal women suffering from vaginal atrophy when compared to cream. Almost 90% of patients who took the cream stopped using it after the first prescription, compared to 58% of patients who were on Novo Nordisk's ($NVO) Vagifem 10 milligram estradiol tablets. The study was based on insurance claims data on more than 30,000 women. More from Medscape (reg. req.) | Abstract

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.